Preparation and application of plant extract for preventing and treating non-alcoholic steatohepatitis

Abstract

The invention discloses preparation and application of a plant extract for preventing and treating non-alcoholic steatohepatitis. The preparation method comprises the following steps: extracting and concentrating boxthorn leaves to serve as a loading solution; and separating and purifying the loading solution by using the synthesized macroporous resin to obtain the boxthorn leaf total flavone extract, the total flavone content is greater than 60%, and the yield is greater than 90%. The method for preparing the extract for preventing and treating the non-alcoholic steatohepatitis is green and environment-friendly, the process route is simple, and animal experiments prove that the obtained extract has a good drug effect on the non-alcoholic steatohepatitis and can be used for developing health-care foods, functional foods and new drugs.

Description

Technical Field

[0001] The invention relates to the preparation and application of a plant extract, in particular to the preparation and application of a plant extract for preventing and treating non-alcoholic fatty hepatitis, and belongs to the technical field of traditional Chinese medicine extraction. Background Art

[0002] Lycium barbarum leaves, also known as Tianjingcao, contain Lycium barbarum polysaccharides, flavonoids and a variety of trace elements and amino acids that are beneficial to the human body. Early studies have shown that Lycium barbarum leaves have anti-fatigue, lipid-lowering and hypoxia-resistant effects. However, they have not been effectively developed and utilized. Therefore, the development and utilization of Lycium barbarum leaves is the key to realizing the high-value utilization of Lycium barbarum by-products.

[0003] Nonalcoholic fatty liver disease (NAFLD) refers to a clinical pathological syndrome characterized by excessive fat deposition in hepatocytes, excluding alcohol and other clear liver-damaging factors. It is an acquired metabolic stress liver injury closely related to insulin resistance and genetic susceptibility. Nonalcoholic steatohepatitis (NASH) is a key stage in the progression of nonalcoholic fatty liver disease, accompanied by hepatocyte spheroidization, inflammation and hepatocyte damage. Nonalcoholic steatohepatitis (NASH), also known as metabolic steatohepatitis, is a clinical syndrome with pathological changes similar to alcoholic hepatitis but without a history of excessive drinking. It is common in middle-aged people, especially overweight and obese individuals. Nonalcoholic steatohepatitis is closely related to metabolic disorders such as obesity, insulin resistance, type 2 diabetes, and hyperlipidemia. Its main characteristics are macrovesicular fatty degeneration of hepatocytes accompanied by hepatocyte damage and inflammation. In severe cases, it can develop into cirrhosis. However, no effective drugs have been developed so far.

[0004] At present, the use of small molecule compounds such as elegansin (CN117503738A), hinokitiol (CN117547525A), benzofuran derivatives (CN117430574A), plant extracts such as clematis extract (CN117338836A), total saponins of radix scutellariae (CN116712500A), and Chinese medicine compositions (CN117224602A, CN116115724A) in the prevention and treatment of non-alcoholic fatty liver disease has been disclosed in China, but there are no reports on the use of total flavonoids extract of wolfberry leaves to prevent and treat non-alcoholic fatty liver disease. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a preparation and application of a plant extract for preventing and treating non-alcoholic fatty liver disease in view of the deficiencies in the prior art. The obtained extract has good pharmacological effects on non-alcoholic fatty liver disease and can be used for the development of health foods, functional foods and new drugs.

[0006] In order to achieve the above object, the present invention adopts the following technical solution: The present invention first provides a method for preparing a plant extract for preventing and treating non-alcoholic fatty hepatitis, comprising the following steps: (1) Total flavonoids extraction from wolfberry leaves: Using wolfberry leaves as raw materials, performing reflux extraction with an extraction solvent to obtain an extract, performing reflux extraction several times and combining the extracts several times, filtering to obtain a filtrate, concentrating the filtrate under reduced pressure to obtain a concentrated solution, and using the concentrated solution as a loading solution; (2) Macroporous resin synthesis: A certain proportion of polymerization monomer, crosslinking agent, functional monomer, porogen and initiator are mixed and dispersed in a deionized water solution containing a dispersant, and a synthesis reaction is carried out under certain conditions. After the synthesis reaction is completed, the solid obtained after filtration is washed with deionized water and ethanol aqueous solution in turn, and then placed in a vacuum drying oven to obtain a macroporous resin; (3) Isolation and purification of total flavonoids from wolfberry leaves: The macroporous resin obtained in step (2) is loaded onto a column, the sample solution obtained in step (1) is passed through the macroporous resin column for adsorption, and then eluted with deionized water and then with ethanol aqueous solution, the eluate is collected, and the eluate is subjected to reduced pressure distillation, and the product is placed in a vacuum drying oven for drying to obtain a total flavonoids extract from wolfberry leaves. The total flavonoids extract from wolfberry leaves is a plant extract for preventing and treating non-alcoholic fatty liver disease.

[0007] In the above technical scheme, in step (1), the extraction solvent is water or an ethanol aqueous solution with a mass fraction of 30% to 80%, the solid-liquid ratio of wolfberry leaves to the extractant is 1:5 to 1:50, the mass of wolfberry leaves is measured in grams, the volume of the extractant is measured in milliliters, the reflux extraction time is 1 to 5 hours each time, and the extraction is performed 1 to 5 times.

[0008] In the above technical solution, in step (1), the filtration is performed using a 10-100 mesh filter; the concentration is performed using a rotary evaporator, the temperature during concentration is 20-80°C, the pressure is 5-30 kPa, and the volume of the concentrate is 1-100 times the mass of the wolfberry leaves, wherein the volume of the concentrate is measured in mL and the mass of the wolfberry leaves is measured in g.

[0009] In the above technical scheme, in step (2), the polymerizable monomer is any one of styrene, acrylates, etc.; the cross-linking agent is any one of divinylbenzene, ethylene glycol dimethacrylate, etc., and its mass is 10% to 800% of the mass of the polymerizable monomer; the functional monomer is any one of vinyl pyrrolidone, vinyl imidazole, vinyl alcohol, vinyl pyridine, etc., and its mass is 10% to 200% of the mass of the polymerizable monomer; the initiator is any one of azobisisobutyronitrile, benzoyl peroxide, etc., and its mass is 1% to 10% of the total mass of the polymerizable monomer, the cross-linking agent and the functional monomer; the porogen is any one of toluene, xylene, n-heptane, etc., and its mass is 10% to 500% of the total mass of the polymerizable monomer, the cross-linking agent and the functional monomer.

[0010] In the above technical scheme, in step (2), the dispersant is any one of gelatin, polyvinyl alcohol, polyvinyl pyrrolidone, etc., and the mass concentration of the dispersant in the deionized water solution containing the dispersant is 0.1~5%; the mass ratio of the total mass of the polymerized monomer, the cross-linking agent and the functional monomer to the deionized water solution containing the dispersant is 1:1~200.

[0011] In the above technical scheme, in step (2), the synthesis of the macroporous resin is carried out by suspension polymerization technology, the reaction is stirred during the reaction, the stirring speed is 40~1000rpm, the reaction temperature is 40~100℃, and the reaction time is 4~48h; the filtration is carried out using a 10~100 mesh filter; the washing is carried out using deionized water, the number of washings is 1~5 times, the washing is carried out using ethanol aqueous solution, the mass fraction of ethanol aqueous solution is 20%~100%, and the number of washings is 1~3 times; the drying is carried out in a drying oven, the drying temperature is 20~80℃, the pressure is 10~30kPa, and the water content is dried to less than 10%.

[0012] In the above technical scheme, in step (3), the macroporous resin is packed in a wet column with a column diameter-to-height ratio of 1:(5-20); the volume of the loading solution is 2 BV-20 BV, and the flow rate is 2 BV / h-20 BV / h; the volume of the deionized water during elution is 2 BV-30 BV, and the flow rate is 5 BV / h-30 BV / h; the volume of the ethanol aqueous solution during elution is 2 BV-20 BV, and the flow rate is 2 BV / h-20 BV / h, and the mass fraction of the ethanol aqueous solution is 20%-90%.

[0013] In the above technical solution, in step (3), the reduced pressure distillation is carried out at a distillation pressure of 2 to 50 kPa and a distillation temperature of 20 to 70 °C; the drying is carried out in the vacuum drying oven at a drying temperature of 20 to 80 °C and a drying pressure of 2 to 40 kPa, and the drying is carried out until the water content is less than 5%.

[0014] The second object of the present invention is to provide a plant extract for preventing and treating non-alcoholic fatty hepatitis prepared by the above method, wherein the total flavonoid content is 60% to 95%.

[0015] The third object of the present invention is to provide an application of the plant extract for preventing and treating non-alcoholic fatty hepatitis in the preparation of drugs for preventing and treating non-alcoholic fatty hepatitis.

[0016] The present invention provides the preparation and application of a plant extract for preventing and treating non-alcoholic fatty hepatitis. A high-purity total flavonoid extract of wolfberry leaves can be prepared from wolfberry leaves. The total flavonoid extract of wolfberry leaves is used in an animal experiment with non-alcoholic fatty hepatitis. The animal experiment is conducted on mice with non-alcoholic fatty hepatitis induced by MCD feed. It can be seen from the animal experiment that the extract of the present invention has a significant therapeutic effect in the prevention and treatment of non-alcoholic fatty hepatitis. The obtained total flavonoid extract of wolfberry leaves has a good effect in preventing and treating non-alcoholic fatty hepatitis, and can be used for the development of health foods, functional foods and drugs. The method has a simple process route, low separation cost, a safe preparation process, and is suitable for industrial production. DETAILED DESCRIPTION

[0017] The specific implementation of the technical solution of the present invention is described in detail below, but the present invention is not limited to the following description: Embodiment 1: A plant extract for preventing and treating non-alcoholic fatty hepatitis is prepared by the following preparation method: (1) Total flavonoids extraction from wolfberry leaves: Weigh 100 g of wolfberry leaves, place in a 5 L round-bottom flask, add 2 L of 60% ethanol solution, reflux at normal pressure for 2 h, and pour out the extract. Add 2 L of 60% ethanol solution to the residue, reflux at normal pressure for 2 h, pour out the extract, and discard the residue. Combine the two extracts, filter with a 40-mesh filter, and concentrate the filtrate using a rotary evaporator at 15 kPa pressure and 50 °C to 1 L, and use the concentrate as the loading solution.

[0018] (2) Macroporous resin synthesis: 5 g styrene, 15 g divinylbenzene, 5 g vinylpyridine, 20 g xylene and 0.5 g azobisisobutyronitrile were mixed and dissolved, and then added into 300 mL aqueous solution containing 1% gelatin. The mixture was reacted at a speed of 500 rpm and a temperature of 75 °C for 20 h. After the reaction, the mixture was filtered with a 100-mesh filter. The solid obtained after filtration was washed three times with water and 90% ethanol respectively, and then dried in a drying oven at a temperature of 50 °C and a pressure of 30 kPa until the water content was less than 10%.

[0019] (3) Isolation and purification of total flavonoids from wolfberry leaves: The macroporous resin obtained in step (2) was wet loaded onto a column, and the column diameter-to-height ratio was 1:8; the sample solution obtained in step (1) was adsorbed on a macroporous resin column, and the volume and flow rate of the sample solution were 10 BV and 2 BV / h, respectively; then deionized water was used for elution, and the deionized water elution volume and flow rate were 5 BV and 15 BV / h, respectively; then the eluent was eluted, and the eluent was 60% ethanol solution, and the elution volume and flow rate were 8 BV and 3 BV / h, respectively; the eluent was collected, and vacuum distilled at 15 kPa and 50°C, and then placed in a drying oven at 20 kPa and 50°C for drying until the water content was less than 5%, thereby obtaining a total flavonoid extract of wolfberry leaves. The total flavonoid content in the extract was determined to be 94.25%, and the yield was 90.18%.

[0020] Embodiment 2: A plant extract for preventing and treating non-alcoholic fatty hepatitis is prepared by the following preparation method: (1) Total flavonoids extraction from wolfberry leaves: Weigh 100 g of wolfberry leaves, place in a 5 L round-bottom flask, add 2.4 L of 60% ethanol solution, reflux at normal pressure for 2 h, and pour out the extract. Add 2.4 L of 60% ethanol solution to the residue, reflux at normal pressure for 2 h, pour out the extract, and discard the residue. Combine the two extracts, filter with a 40-mesh filter, and concentrate the filtrate using a rotary evaporator at 20 kPa pressure and 50 °C to 1 L, and use the concentrate as the loading solution.

[0021] (2) Macroporous resin synthesis: 10 g styrene, 10 g divinylbenzene, 5 g vinylpyrrolidone, 20 g xylene and 0.3 g azobisisobutyronitrile were mixed and dissolved, and then added into 300 mL of aqueous solution containing 1% gelatin. The mixture was reacted at a speed of 450 rpm and a temperature of 80 °C for 24 h. After the reaction, the mixture was filtered with an 80-mesh filter. The solid obtained after filtration was washed twice with water and 80% ethanol, respectively, and then dried in a drying oven at a temperature of 50 °C and a pressure of 30 kPa until the water content was less than 10%.

[0022] (3) Isolation and purification of total flavonoids from wolfberry leaves: The macroporous resin obtained in step (2) was wet loaded onto a column, and the column diameter-to-height ratio was 1:10; the sample solution obtained in step (1) was adsorbed on a macroporous resin column, and the volume and flow rate of the sample solution were 10 BV and 3 BV / h, respectively; then deionized water was used for elution, and the deionized water elution volume and flow rate were 5 BV and 15 BV / h, respectively; then the eluent was used for elution, and the eluent was 60% ethanol solution, and the elution volume and flow rate were 8 BV and 4 BV / h, respectively; the eluent was collected, and vacuum distilled at 15 kPa and 50°C, and then placed in a drying oven at 20 kPa and 50°C for drying until the water content was less than 5%, thereby obtaining a total flavonoid extract of wolfberry leaves. The total flavonoid content in the extract was determined to be 95.38%, and the yield was 91.06%.

[0023] Embodiment 3: A plant extract for preventing and treating non-alcoholic fatty hepatitis is prepared by the following preparation method: (1) Total flavonoids extraction from wolfberry leaves: Weigh 100 g of wolfberry leaves, place in a 5 L round-bottom flask, add 2 L of 70% ethanol solution, reflux at normal pressure for 2 h, and pour out the extract. Add 2 L of 70% ethanol solution to the residue, reflux at normal pressure for 2 h, pour out the extract, and discard the residue. Combine the two extracts, filter with a 40-mesh filter, and concentrate the filtrate using a rotary evaporator at 20 kPa pressure and 50 °C to 1 L, and use the concentrate as the loading solution.

[0024] (2) Macroporous resin synthesis: 15 g styrene, 5 g divinylbenzene, 5 g vinylpyrrolidone, 20 g xylene and 0.3 g azobisisobutyronitrile were mixed and dissolved, and then added into 300 mL of aqueous solution containing 0.5% gelatin. The mixture was reacted at a speed of 450 rpm and a temperature of 80 °C for 24 h. After the reaction, the mixture was filtered with a 100-mesh filter. The solid obtained after filtration was washed twice with water and 60% ethanol, respectively, and then dried in a drying oven at a temperature of 50 °C and a pressure of 30 kPa until the water content was less than 10%.

[0025] (3) Isolation and purification of total flavonoids from wolfberry leaves: The macroporous resin obtained in step (2) was wet loaded onto a column, and the column diameter-to-height ratio was 1:10; the sample solution obtained in step (1) was adsorbed on a macroporous resin column, and the volume and flow rate of the sample solution were 10 BV and 3 BV / h, respectively; then deionized water was used for elution, and the deionized water elution volume and flow rate were 5 BV and 15 BV / h, respectively; then the eluent was used for elution, and the eluent was 60% ethanol solution, and the elution volume and flow rate were 8 BV and 4 BV / h, respectively; the eluent was collected, and vacuum distilled at 15 kPa and 50°C, and then placed in a drying oven at 20 kPa and 50°C for drying until the water content was less than 5%, thereby obtaining a total flavonoid extract of wolfberry leaves. The total flavonoid content in the extract was determined to be 94.83%, and the yield was 90.28%.

[0026] Verification Example 1: The wolfberry leaf extract obtained in Example 1 was used as the raw material for animal experiments. Male Kunming mice weighing 18-22g were taken and randomly divided into a control group, a model group, a low-dose group (1.0 original drug g / kg), and a high-dose group (10.0 original drug g / kg) according to their weight after adaptive feeding. Except for the control group, which was given ordinary feed, the remaining groups were given MCD feed for 1 month. At the same time, the drug-administered group was gavaged once a day with a volume of 10 mL / kg for 1 month. The control group and the model group were gavaged with an equal volume of water. After the last dose, the mice were fasted but not water-free. After 14 hours, serum was taken to detect AST, ALT, TC, TG, HDL, and LDL. The liver was taken to weigh the wet weight and calculate the liver index.

[0027] Table 1 Effects of total flavonoids extract from wolfberry leaves on body weight and liver indexes in mice Group n Weight (g) Liver index (mg / 10g) Control group 7 40.1±4.11*** 407.26±18.54*** Model Group 8 14.86±0.66 633.98±129.21 Low dose group 7 15.23±0.63 653.82±122.91 High dose group 7 15.71±0.95 495.81±66.61* Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001.

[0028] As shown in Table 1, compared with the control group, the body weight of mice in the model group was significantly reduced and the liver index was significantly increased. Compared with the model group, the liver index of mice in the high-dose group was significantly reduced.

[0029] Table 2 Effects of total flavonoids extract from wolfberry leaves on serum liver function in mice Group n ALT (U / L) AST (U / L) TBA (µmol / L) Control group 7 42.57±10.07*** 198.29±69.88*** 2.11±0.89*** Model Group 8 941±421.12 1056±326.95 30.76±7.73 Low dose group 7 1033.29±1255.73 644.33±296.8* 64±47.82 High dose group 7 256.14±156.02** 370.71±172.01*** 77.06±53.41 Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001.

[0030] As shown in Table 2, compared with the control group, the ALT, AST, and TBA in the serum of the mice in the model group were significantly increased, and the liver function was significantly decreased. Compared with the model group, the high-dose group could significantly reduce the ALT content in the serum of mice; each drug-treated group could significantly reduce the AST content in the serum of mice.

[0031] Table 3 Effects of total flavonoids extract from wolfberry leaves on blood lipids in mice Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001.

[0032] As shown in Table 3, compared with the control group, the TG, TC, HDL, and LDL levels in the serum of the mice in the model group were significantly reduced. Compared with the model group, both the low-dose group and the high-dose group could significantly increase the TC level in the serum of the mice; both the low-dose group and the high-dose group could significantly increase the HDL level in the serum of the mice.

[0033] Table 4 Effects of total flavonoids from wolfberry leaves on liver lipids in mice Group n TG (mg / gprot) TC (mg / prot) Comparison 7 325.43±141.94*** 0.71±0.16 Model Group 8 628.28±78.18 0.62±0.23 Low dose group 7 611.76±106.88 0.7±0.29 High dose group 7 426.43±94.19** 0.4±0.07* Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001.

[0034] As shown in Table 4, compared with the control group, the TG content in the liver of the mice in the model group was significantly increased. Compared with the model group, the high-dose group could significantly reduce the TG content in the liver of the mice; the high-dose group could significantly reduce the TC content in the liver of the mice.

[0035] The above examples are only for illustrating the technical concept and technical features of the present invention, and cannot be used to limit the protection scope of the present invention. Any equivalent transformation or modification made according to the essence of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a plant extract for preventing and treating non-alcoholic fatty hepatitis, characterized in that: The following steps are involved: (1) Total flavonoids extraction from wolfberry leaves: Using wolfberry leaves as raw materials, performing reflux extraction with an extraction solvent to obtain an extract, performing reflux extraction several times and combining the extracts several times, filtering to obtain a filtrate, concentrating the filtrate under reduced pressure to obtain a concentrated solution, and using the concentrated solution as a loading solution; (2) Macroporous resin synthesis: A certain proportion of polymerization monomer, crosslinking agent, functional monomer, porogen and initiator are mixed and dispersed in a deionized water solution containing a dispersant, and a synthesis reaction is carried out under certain conditions. After the synthesis reaction is completed, the solid obtained after filtration is washed with water and ethanol aqueous solution in turn, and then placed in a vacuum drying oven to obtain a macroporous resin; (3) Isolation and purification of total flavonoids from wolfberry leaves: The macroporous resin obtained in step (2) is loaded onto a column, the sample solution obtained in step (1) is passed through the macroporous resin column for adsorption, and then eluted with deionized water and then with ethanol aqueous solution, the eluate is collected, and the eluate is subjected to reduced pressure distillation, and the product is placed in a vacuum drying oven for drying to obtain a total flavonoids extract from wolfberry leaves. The total flavonoids extract from wolfberry leaves is a plant extract for preventing and treating non-alcoholic fatty liver disease.

2. The preparation method according to claim 1, characterized in that: In step (1), the extraction solvent is water or an ethanol aqueous solution with a mass fraction of 30% to 80%, the solid-liquid ratio of wolfberry leaves to the extractant is 1:5 to 1:50, the reflux extraction time is 1 to 5 hours each time, and the extraction is performed 1 to 5 times; the filtration is performed using a 10 to 100 mesh filter; the concentration is performed using a rotary evaporator, the temperature during concentration is 20 to 80°C, the pressure is 5 to 30 kPa, and the volume of the concentrate is 1 to 100 times the mass of the wolfberry leaves, wherein the volume of the concentrate is measured in mL and the mass of the wolfberry leaves is measured in g.

3. The preparation method according to claim 1, characterized in that: In step (2), the polymerizable monomer is any one of styrene, acrylates, etc.; the cross-linking agent is any one of divinylbenzene, ethylene glycol dimethacrylate, etc., and its mass is 10% to 800% of the mass of the polymerizable monomer; the functional monomer is any one of vinyl pyrrolidone, vinyl imidazole, vinyl alcohol, vinyl pyridine, etc., and its mass is 10% to 200% of the mass of the polymerizable monomer; the initiator is any one of azobisisobutyronitrile, benzoyl peroxide, etc., and its mass is 1% to 10% of the total mass of the polymerizable monomer, the cross-linking agent and the functional monomer; the porogen is any one of toluene, xylene, n-heptane, etc., and its mass is 10% to 500% of the total mass of the polymerizable monomer, the cross-linking agent and the functional monomer.

4. The preparation method according to claim 1, characterized in that: In step (2), the dispersant is any one of gelatin, polyvinyl alcohol, polyvinyl pyrrolidone, etc., and the mass concentration of the dispersant in the deionized water solution containing the dispersant is 0.1~5%; the mass ratio of the total mass of the polymerized monomer, the cross-linking agent and the functional monomer to the deionized water solution containing the dispersant is 1:1~200.

5. The preparation method according to claim 1, characterized in that: In step (2), the synthesis of the macroporous resin is carried out by suspension polymerization technology, the reaction is stirred at a speed of 40-1000 rpm, the reaction temperature is 40-100°C, and the reaction time is 4-48 h; the filtration is carried out using a 10-100 mesh filter; the washing is carried out using deionized water for 1-5 times, the washing is carried out using an ethanol aqueous solution with a mass fraction of 20-100% and a washing frequency of 1-3 times; the drying is carried out in a drying oven at a temperature of 20-80°C and a pressure of 10-30 kPa, and the drying is carried out until the water content is less than 10%.

6. The preparation method according to claim 1, characterized in that: In step (3), the macroporous resin is packed in a wet column with a column diameter-to-height ratio of 1:(5-20); the volume of the loading solution is 2 BV-20 BV, and the flow rate is 2 BV / h-20 BV / h; the volume of the deionized water during elution is 2 BV-30 BV, and the flow rate is 5 BV / h-30 BV / h; the mass fraction of the ethanol aqueous solution is 20%-90%, and the volume of the ethanol aqueous solution during elution is 2 BV-20 BV, and the flow rate is 2 BV / h-20 BV / h.

7. The preparation method according to claim 1, characterized in that: In step (3), the reduced pressure distillation is carried out at a distillation pressure of 2 to 50 kPa and a distillation temperature of 20 to 70°C; the drying is carried out in a vacuum drying oven at a drying temperature of 20 to 80°C and a drying pressure of 2 to 40 kPa until the water content is less than 5%.

8. A plant extract for preventing and treating nonalcoholic fatty hepatitis obtained by the preparation method according to any one of claims 1 to 7, characterized in that: The plant extract for preventing and treating non-alcoholic fatty hepatitis has a total flavonoid content of 60% to 95%.

9. Use of the plant extract for preventing and treating non-alcoholic fatty hepatitis according to claim 8 in the preparation of drugs for preventing and treating non-alcoholic fatty hepatitis.